4D Molecular Therapeutics, Inc. (FDMT)
After hours:
| Previous close | 23.53 |
| Open | 23.45 |
| Bid | 23.18 x 200 |
| Ask | 23.27 x 400 |
| Day's range | 22.75 - 23.85 |
| 52-week range | 9.44 - 36.25 |
| Volume | |
| Avg. volume | 1,219,238 |
| Market cap | 1.189B |
| Beta (5Y monthly) | 2.86 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
Conducted initial pivotal study interactions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA); Company has clear registration path for 4D-710 for treatment of cystic fibrosis (CF) lung disease in people with CF (pwCF) who are ineligible for or cannot tolerate approved CF modulator therapies AEROW clinical trial Phase 2 Expansion Cohort dose selection and initiation expected in Q2 2024, with pivotal trial initiation anticipated in H2 2025Initial GMP-ready suspe
- GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in fireside chats at upcoming investor conferences in March. Members of the management team will also be available for one-on-one meetings. Leerink Partners Global Biopharma Conference 2024
- GlobeNewswire
4DMT Reports Full Year 2023 Financial Results and Operational Highlights
Presented positive interim data from randomized Dose Expansion cohort of the Phase 2 PRISM study evaluating 4D-150 in wet AMD patients with severe disease activity and high treatment burden, enabling advancement into Phase 3 pivotal development, with initiation expected in Q1 2025Positive interim clinical data for 4D-710 in cystic fibrosis and 4D-310 in Fabry disease continue to demonstrate the potential of these product candidates and the efficient delivery, transgene expression and clinical ac
